What are the leading sector stocks in biopharmaceutical stocks?
China's leading pharmaceutical stocks are companies that have a leading position and market share in China's pharmaceutical industry. These companies include Xi'an Janssen Pharmaceuticals, Hysco Pharmaceuticals, Hengrui Pharmaceuticals, China Biopharmaceuticals, Shiyao Group, Jiuzhitang Pharmaceuticals, and Coren Pharmaceuticals. The following Xiao Biao brought biopharmaceutical stocks what plate leading stocks, we take a look at it, I hope to bring reference.
Biomedical stocks have what plate leading stocks
A, Hengrui Medicine (600276), the first domestic innovative drugs. The main product lines are anti-tumor, anesthesia, contrast agents and so on. The company's net
return on assets for many years to maintain more than 23%, net profit for many years to maintain a rate of growth of more than 20%. The company's R & D strength is very strong,
management team is relatively good, sales capacity is also very strong. Second, Aier Ophthalmology (300015), the first share of domestic ophthalmic hospital chain. Mainly to provide patients with a variety of ophthalmic diseases diagnosis, ___
and medical optometry and other ophthalmic medical services. The company's return on net assets has remained at about 20% for many years, and its net profit has maintained a growth rate of over 30%
for many years. The company's business model is relatively excellent, operating ability and brand reputation continues to strengthen. Third, Myriad Medical (300760), the first domestic medical equipment. The main product lines are life and information support, in vitro diagnostics, medical
imaging and so on. The company's return on net assets for many years to maintain more than 25%, net profit for many years to maintain a rate of growth of more than 25%. The company as
for the completion of the global layout of the medical device leader, high-end, platform steadily advancing, the position is very solid, huge space in the long term. Fourth, Changchun High-tech (000661), the first domestic biopharmaceutical stocks. The main product lines are growth hormone, syncytial virus _____ vaccine. The company
the return on net assets for many years to maintain more than 16%, net profit for many years to maintain more than 30% growth rate. The company as China's biomedical
pharmaceutical leader, performance exceeds the expected growth. Fifth, WuXi AppTec (603259), the first share of domestic medical research and development services. The main business is the discovery of small molecule chemical drugs, R & D and production
production of a full range of integrated platform services. The company's return on net assets has remained above 20% for many years, and its net profit has maintained a growth rate of over 25% for many years
. The company is the world's leading pharmaceutical R & D service platform, market space is broad, performance is expected to maintain rapid growth. Six, Tigermed (300347), the leading clinical contract research organization (CRO) leader. The main business is for pharmaceutical product development
For Ⅰ to Ⅳ clinical trial technical services, data management and other clinical research services. The company's return on net assets in the past two years to 17%
about, net profit for many years to maintain a rate of growth of 56% or more. Seven, I Wu biology (300357), the domestic desensitization diagnosis and treatment of the first stock. The company's dust mite drops to maintain high growth, the heavyweight product Huanghua
Artemisia pollen sublingual drops into the site verification, is expected to be approved for listing in 2020. The company's return on net assets has remained above 21% for many years
and its net profit has maintained a growth rate of over 25% for many years. The company as China's only sublingual desensitization leading enterprises, the competitive landscape
excellent, market share of more than 80%, the company's long-term growth potential. Eight, Tongze medical (600763), the first domestic oral chain shares. The company through the "hospital can be copied + doctors can be copied + team can be copied"
model, to start the layout of the dental hospital chain. The company's return on net assets for many years to maintain at about 23%, net profit for many years to maintain a rate of growth of about 50%. China's oral market space is vast, the company is expected to be in the aging population and consumer upgrading two trends, to obtain rapid development. Nine, An___ biological (603658), the domestic IVD leading stocks. The company is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and their supporting instruments. The company's return on net assets has remained at about 30% for many years, and the net profit has maintained a growth rate of more than 25% for many years. Chemiluminescence industry will enter the era of differentiation. With 70% of biological raw material assets, mainstream projects, assembly lines and other advantages, the company is expected to continue to replace foreign and other domestic products, to maintain sustained growth. Ten, Hualan Bio (002007), the leading stock of domestic blood products. The company's main product lines are blood products and ____ seedling products. The company's return on net assets has been maintained at about 19% for many years, and the net profit has been growing at about 30% for many years. With the slow recovery of the domestic blood products industry and the continued release of influenza ___ vaccine, the company's performance is expected to be further improved.
Biomedical Stocks Leading at a Glance
On March 21, three pharmaceutical companies with a market capitalization of more than $100 billion announced their 2022 annual reports. Among them, WuXi AppTec's revenue hit a record high last year, net profit soared 70%; main ___ seedling and in vitro diagnostics of Wantai Biological's revenue is close to doubling, net profit growth of more than 130%; another ___ seedling enterprise Zhifei Biological net profit declined by 26% year-on-year.
Financial Investment Newspaper
According to WIND statistics, 19 companies in the Shenwan pharmaceutical and biological industries have released their annual reports, of which 16 have reported year-on-year growth in net profit. Perhaps it is supported by strong results, March 21, the pharmaceutical sector strong surge, WuXi AppTec shares jumped 8.5%.
PharmaTech business record
Pharmaceutical research and development services industry, WuXi AppTec's annual report shows that in 2022, the company realized operating income of 39.355 billion yuan, a new record, an increase of 71.84% year-on-year; attributable to shareholders of the parent company's net profit of 8.814 billion yuan, a year-on-year increase of 72.91%.
By business, WuXi AppTec's chemical business, testing business, biology business, cell and gene therapy CTDMO business gained growth, of which the revenue of the chemical business increased by more than 105%. Only the domestic new drug R&D services division saw a 22.49% year-on-year decline in revenue, with revenue of 970 million yuan in the period.
The growth of WuXi AppTec's new customers was also more obvious last year. In its annual report, WuXi AppTec said that in 2022, the company added more than 1,400 new customers and more than 5,950 active customers. The company's revenue from the original customers 37.781 billion yuan, an increase of 77% year-on-year; revenue from new customers 1.573 billion yuan. Revenue from enterprises was $18.421 billion, an increase of 174% year-on-year; and revenue from other global customers was $20.934 billion, an increase of 30% year-on-year.
Meanwhile, WuXi PharmaTech's research and development expenses last year rose sharply by more than 70% to 1.614 billion yuan, accounting for 4.1% of revenue. According to WuXi AppTec, the increase in R&D expenses was mainly due to the company's continued investment in R&D to further strengthen its ability to serve new molecule types such as PROTAC, oligonucleotide drugs, peptide drugs, coupled drugs, double antibiotics, cells and genes.
Two ___ seedling leaders performance towards the opposite
In addition to WuXi AppTec, the two main products of the ___ seedling of the 100 billion market capitalization of the enterprise Zhifei Biologicals and Vantage Biologicals also announced the annual report.
Zhi Fei Bio annual report shows that in 2022, the company realized operating income of 38.264 billion yuan, an increase of 24.83% year-on-year; net profit attributable to shareholders of the parent company of 7.539 billion yuan, a year-on-year decrease of 26.15%. Basic earnings per share of 4.711 yuan, a year-on-year decrease of 26.15%.
For the reasons for the decline in performance, Zhifei Biological believes that in 2022, affected by objective factors, the company's part of the product market demand and the competitive landscape has undergone a major change, and its sales volume compared with last year fell significantly. However, with the improvement of people's health awareness and willingness to vaccinate, the market potential of non-exempt ___ planning class ___ vaccine market has been continuously stimulated, and the market space has further expanded.
In 2022, Zhifei Bio's R&D expenses amounted to 854 million yuan, an increase of 54.56% year-on-year.
Zhi Fei biological main business is ___ vaccine, biological products research and development. Its own products include ACYW135 polysaccharide ___ vaccine, AC binding ___ vaccine, Hib ___ vaccine and AC polysaccharide ___ vaccine. Agency products include Merck Sharp & Dohme's quadrivalent HPV ___ vaccine, nine-valent HPV ___ vaccine, pentavalent rotavirus ___ vaccine, 23-valent pneumonia ___ vaccine and inactivated hepatitis A ___ vaccine.
Vantage Bio realized revenue of 11.185 billion yuan last year, up 94.51 percent year-on-year; net profit attributable to shareholders of listed companies of 4.736 billion yuan, up 134.27 percent year-on-year; and basic earnings per share of 5.31 yuan.
Wantai biological main ___ vaccine and in vitro diagnostics. Among them, ___ seedling and in vitro diagnostics revenue both long, ___ seedling segment revenue growth of more than 152%. Diagnostic division realized net profit of 817,665,500 yuan, accounting for 16.81%; ___ seedling division realized net profit of 404,563,500 yuan, accounting for 83.19%.
Wantai Bio said the company's bivalent cervical cancer ___ vaccine continues to maintain production and sales, revenue and profits continue to maintain high growth. Its design capacity of 30 million pcs per year, sales exceeded 25 million pcs, and successively won the listing license of Morocco, Nepal, Thailand, the Democratic Republic of Congo (DRC) 4 countries; nine-valent HPV ___ vaccine phase III clinical trials are progressing well.
Brokerage firms optimistic about the full recovery of conventional medical demand
In addition to the above three leading pharmaceutical stocks, the Shenwan primary industry classification, pharmaceutical and biological plate in another 16 companies published their annual reports. Of the 19 companies, 16 reported positive year-on-year growth in net profit, with Wantai Bio and WuXi Kande leading the way.
And from the market performance, in the strong performance of the support, March 21, the pharmaceutical plate strong rebound, Shenwan Pharmaceutical and Biological Plate soared 2.4%, Purex, Panlong Pharmaceuticals shares rose 14.39% and 10%, respectively, while WuXi AppTec shares soared 8.46%, turnover reached 4.4 billion yuan, the stock closed at 80.26 yuan. Shares of Changchun High-Tech, Jiuzhou Pharmaceutical and Kanglong Huacheng all rose more than 7 percent, while Wantai Bio rose more than 3.7 percent.
The first securities said that with the end of the ___策压制因素, the pharmaceutical industry "___策底" features significant valuation contraction has ended, at this stage of the pharmaceutical plate already has a high cost-effective investment, once again ushered in the configuration of a good opportunity. From the operating trend point of view, ______ for pharmaceutical and medical device product type companies, especially the pharmaceutical industry company performance perturbation has been gradually approaching the end, the follow-up is about to enter a new cycle of earnings growth.
Shenwan Hongyuan expects that 2023 is expected to be a full recovery of conventional medical demand. The healthcare section of the _____ work report fully recognizes the success of cost control _____ policies such as collective purchasing in reducing the healthcare burden over the past few years. It also mentioned the need to promote the expansion and sinking of high-quality medical resources, strengthen the protection of elderly care services, and improve the fertility support ____ policy in the future. It is expected that continued cost control is still the main line of ____ policy, independent innovation, national medicine, industry chain independent control, AI + medical, vitamin price increases, etc. for the current investment direction.
What are the leading stocks of stock medicine
Domestic generic leading stocks: Hengrui Medicine, East China Pharmaceuticals, Huahai Pharmaceuticals, Primavera Pharmaceuticals, Jingxin Pharmaceuticals, Xinlitai.
The second generation insulin leader Tonghua Dongbao, blood products leader Hualan Bio, ___ seedling leader Kangtai Bio (this is controversial, need to break down the varieties), monoclonal antibody leader Fuhong Hanlin, etc. (monoclonal antibody is more decentralized, the layout of the enterprise, Haizheng Biologicals, Jiahe, etc.), growth hormone leader Changchun High-tech, anti-allergy biopharmaceuticals leader I Wu Bio.
Baiyunshan 600332: Baiyunshan's brand awareness and reputation in the national consumer has a great influence and attraction, is one of China's most valuable pharmaceutical brands; Kun Pharmaceutical Group 600422: 2015 annual profit of the pharmaceutical industry is expected to be 260.2 billion yuan, an increase of 19% year-on-year growth rate decreased by 0.4 percentage points.
The list of "leading pharmaceutical" stocks includes: Myriad Medical, Hengrui Pharmaceuticals, Shanghai Pharmaceuticals, Baiyunshan, Changchun High-tech.
What are the leading pharmaceutical stocks in China
Hello, there are these Hengrui Pharmaceuticals 600276: a leading innovative drug company, the proportion of research and development is constantly increasing, but also China's largest anti-tumor, surgical drugs and contrast media research and production base.
Foreign capital heavy positions in the list of "pharmaceutical leading" stocks include: Myriad Medical, Hengrui Pharmaceuticals, Shanghai Pharmaceuticals, Baiyunshan, Changchun High-tech.
Henry Pharmaceuticals (600276), the first share of domestic innovative drugs. The main product lines are anti-tumor, anesthesia, contrast agents and so on. The company's return on net assets for many years to maintain more than 23%, net profit for many years to maintain a rate of growth of more than 20%. The company's R&D strength is very strong, the management team is relatively good, and the sales capacity is also very strong.
Medical aesthetics, or medical aesthetics for short, is a cosmetic method of repairing and reshaping a person's appearance and various parts of the human body by using traumatic or irreversible medical techniques such as medicines, surgeries, and medical devices.
The leading stocks of listed pharmaceutical companies are Tencent Holdings Limited, Pharmaceutical Biologics, and China Biopharmaceuticals. Tencent Holdings Ltd (00700.HK): Tencent's pharmaceutical subsidiary, Tencent Healthcare, is one of China's leading Internet medical platforms and one of the leading companies in the pharmaceutical industry.
2023 pharmaceutical listed companies leading stocks are as follows: ST Yikang (000150), up 45%. ST Fu Ren (600781), up 72%. Sincerity Pharmaceuticals (603811), up 77%. Chengdu pilot (688222), up 62%. Xingqi eye drug (300573), up 69%.
Pharmaceutical concept of listed companies which
Hengrui Medicine (600276): the company's business has a pharmaceutical research and development, production and sales.
Warmin (603259): the company is engaged in pharmaceutical research and development services.
Ayer Eye (300015): the company's main business is ophthalmic medical services and optometric medical services.
Zhi Fei biological (300122): the company's business has a vaccine, biological products research and development, production and sales.
Pientzehuang (600436): the company's main business is manufacturing of proprietary Chinese medicines and distribution of medicines.
Yunnan Baiyao (000538): the company's business has the research and development, production and sales of medicine.
Fosun Pharma (600196): the company's business has pharmaceutical manufacturing and research and development.
Tiger Pharmaceuticals (300347): the company's main business is professional clinical research services.
Huadong Medicine (000963): the company's business has pharmaceutical industrial production and pharmaceutical commercial distribution.
Junshi Bio (688180): the company's business includes biopharmaceuticals.
Changchun Gaoxin (000661): the company's business has the research and development, production and sales of biopharmaceuticals and proprietary Chinese medicines.
Kanglonghua (300759): the company is engaged in small molecule drug research and development services.
Shanghai Pharmaceutical (601607): the company is mainly engaged in pharmaceutical research and development and manufacturing, distribution and retail.
Tongrentang (600085): the company's main business is the production and sale of proprietary Chinese medicines.
Watson Biological (300142): the company's main business is human vaccines and other biotechnology drug set of research and development, production and sales.